FDA Drug recall D-928-2014
ASPIRIN, Tablet, 325 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536330501
- FDA Drug
- Class II
- terminated
- Published 2014-01-29
On 2014-01-29 the FDA classified a Class II recall of ASPIRIN, Tablet, 325 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536330501 by Aidapak Services, citing labeling: Label Mixup: ASPIRIN, Tablet, 325 mg may have potentially been mislabeled as one of the following drugs: PANCRELIPASE DR, Capsule, 0 mg, NDC 42865010302, Pedigree: W0033….
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-928-2014 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2013-07-02 |
| Published | 2014-01-29 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Aidapak Services |
| Distribution | AZ, CA, OR, WA |
Product
ASPIRIN, Tablet, 325 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536330501.
Reason
Labeling: Label Mixup: ASPIRIN, Tablet, 325 mg may have potentially been mislabeled as one of the following drugs: PANCRELIPASE DR, Capsule, 0 mg, NDC 42865010302, Pedigree: W003354, EXP: 6/19/2014; acetaZOLAMIDE, Tablet, 250 mg, NDC 51672402301, Pedigree: W003524, EXP: 6/21/2014; METOPROLOL TARTRATE, Tablet, 25 mg, NDC 00378001801, Pedigree: W002535, EXP: 6/3/2014; RIVAROXABAN, Tablet, 20 mg,
Identifiers
| code_info | ASPIRIN, Tablet, 325 mg has the following codes: Pedigree: W003355, EXP: 6/19/2014; Pedigree: W003525, EXP: 6/21/201…ASPIRIN, Tablet, 325 mg has the following codes: Pedigree: W003355, EXP: 6/19/2014; Pedigree: W003525, EXP: 6/21/2014; Pedigree: W002573, EXP: 6/3/2014; Pedigree: W002624, EXP: 6/4/2014. |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-928-2014%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.